BRIEF-Caredx Reiterates Position That It Does Not Infringe The ‘544 Patent, Injunction Motion Is Irrelevant

Reuters05-29

May 29 (Reuters) - CareDx Inc :

* CAREDX REITERATES POSITION THAT IT DOES NOT INFRINGE THE ‘544 PATENT, INJUNCTION MOTION IS IRRELEVANT

* CAREDX INC - INJUNCTION MOTION HAS NO IMPACT ON CAREDX'S BUSINESS OR PATIENT AND CLINICIAN ACCESS TO ALLOSURE OR ALLOMAP

* CAREDX INC - UNDERLYING VALIDITY OF '544 PATENT ALSO REMAINS SUBJECT TO JUDICIAL REVIEW.

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2439525355?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-29 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2439525355","market":"us","top_or_hot":-1,"title":"BRIEF-Caredx Reiterates Position That It Does Not Infringe The ‘544 Patent, Injunction Motion Is Irrelevant","media":"Reuters","content":"<html><body><p>May 29 (Reuters) - <a href=\"https://laohu8.com/S/CDNA\">CareDx</a> Inc   :</p><p>   * CAREDX REITERATES POSITION THAT IT DOES NOT INFRINGE THE ‘544 PATENT, INJUNCTION MOTION IS IRRELEVANT</p><p>   * CAREDX INC - INJUNCTION MOTION HAS NO IMPACT ON CAREDX'S BUSINESS OR PATIENT AND CLINICIAN ACCESS TO ALLOSURE OR ALLOMAP</p><p>   * CAREDX INC - UNDERLYING VALIDITY OF '544 PATENT ALSO REMAINS SUBJECT TO JUDICIAL REVIEW.</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Caredx Reiterates Position That It Does Not Infringe The ‘544 Patent, Injunction Motion Is Irrelevant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Caredx Reiterates Position That It Does Not Infringe The ‘544 Patent, Injunction Motion Is Irrelevant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-29 20:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>May 29 (Reuters) - CareDx Inc   :   * CAREDX REITERATES POSITION THAT IT DOES NOT INFRINGE THE ‘544 PATENT, INJUNCTION MOTION IS IRRELEVANT   * CAREDX INC - INJUNCTION MOTION HAS NO IMPACT ON CAREDX'S...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDNA","symbol_name":"CareDx","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2439525355","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2439525355","pubTimestamp":1716984517,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"May 29  - CareDx Inc   :   * CAREDX REITERATES POSITION THAT IT DOES NOT INFRINGE THE ‘544 PATENT, INJUNCTION MOTION IS IRRELEVANT   * CAREDX INC - INJUNCTION MOTION HAS NO IMPACT ON CAREDX'S BUSINESS OR PATIENT AND CLINICIAN ACCESS TO ALLOSURE OR ALLOMAP   * CAREDX INC - UNDERLYING VALIDITY OF '544 PATENT ALSO REMAINS SUBJECT TO JUDICIAL REVIEW.Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDNA":"CareDx","BK4139":"生物科技"},"translate_title":"简要-Caredx重申其立场，即它没有侵犯’544专利，禁令动议是不相关的","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":1},"content_text":"May 29 (Reuters) - CareDx Inc   :   * CAREDX REITERATES POSITION THAT IT DOES NOT INFRINGE THE ‘544 PATENT, INJUNCTION MOTION IS IRRELEVANT   * CAREDX INC - INJUNCTION MOTION HAS NO IMPACT ON CAREDX'S BUSINESS OR PATIENT AND CLINICIAN ACCESS TO ALLOSURE OR ALLOMAP   * CAREDX INC - UNDERLYING VALIDITY OF '544 PATENT ALSO REMAINS SUBJECT TO JUDICIAL REVIEW.Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2439525355"}